Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR3 | P25089 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.30 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.30 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30829440 | 0.80 | ASGR1 (0.32) | PDK2ASGR1 | |
| SCHEMBL6795328 | 0.80 | FPR3 (0.34) | FPR3FPR2PDK2 | |
| SCHEMBL31703654 | 0.75 | HDAC6 (0.33) | FPR3FPR2HDAC6PDK2ASGR1 | |
| SCHEMBL15125117 | 0.73 | ASGR1 (0.31) | FPR3FPR2HDAC6ASGR1NFKB1 | |
| SCHEMBL23282418 | 0.72 | ASGR1 (0.40) | FPR3FPR2HDAC6PDK2ASGR1 | |
| SCHEMBL15116573 | 0.72 | CYP4F2 (0.33) | FPR3FPR2HDAC6PDK2ASGR1 | |
| SCHEMBL4144702 | 0.72 | HDAC6 (0.30) | HDAC6 | |
| SCHEMBL4137259 | 0.72 | PDK2 (0.32) | FPR3FPR2HDAC6PDK2ASGR1 | |
| SCHEMBL499275 | 0.72 | HDAC6 (0.38) | HDAC6PDK2ASGR1NFKB1NFKB2 | |
| SCHEMBL4150342 | 0.72 | SLC6A2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | OHI NORIHITO | 2009-02-26 | — | — | US | disclosed |
| US-7429609-B2 | Pyrazole compound and medicinal composition containing the same | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-20050208582-A1 | Pyrazole compounds and pharmaceutical compositions comprising the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1510516-A1 | PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | CNKSR1, NR3C2, CSNK2B | FPR3 992/4885FPR2 938/4885HDAC6 316/4885 |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | FPR3 952/4885FPR2 887/4885HDAC6 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.